Highlights of our peer-reviewed research in the healthcare and mainstream press.
In Friday’s Morning eHealth daily report, POLITICO’s Darius Tahir discussed HIPAA in the age of cloud computing and mentioned a recent study in The American Journal of Managed Care (AJMC) that proposed expanding state prescription drug monitoring programs. The authors suggest expanding these programs to all prescription drugs, instead of just opiates.
Aledade’s report providing an inside look at the accountable care organizations (ACOs) the company has helped start continues to receive attention. As part of a Q&A with Aledade’s Farzad Mostashari, MD, Healthcare Informatics’ Rajiv Leventhal noted the report Mostashari co-wrote for AJMC and how the authors looked at ways CMS could prove the Medicare ACO programs.
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More